Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Income towards Parent Company: 2018-2024

Historic Income towards Parent Company for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to -$322.1 million.

  • Avidity Biosciences' Income towards Parent Company fell 117.13% to -$174.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.5 million, marking a year-over-year decrease of 95.95%. This contributed to the annual value of -$322.1 million for FY2024, which is 52.18% down from last year.
  • Latest data reveals that Avidity Biosciences reported Income towards Parent Company of -$322.1 million as of FY2024, which was down 52.18% from -$211.6 million recorded in FY2023.
  • Avidity Biosciences' Income towards Parent Company's 5-year high stood at -$44.3 million during FY2020, with a 5-year trough of -$322.1 million in FY2024.
  • Its 3-year average for Income towards Parent Company is -$235.9 million, with a median of -$211.6 million in 2023.
  • Data for Avidity Biosciences' Income towards Parent Company shows a maximum YoY slumped of 166.37% (in 2021) over the last 5 years.
  • Over the past 5 years, Avidity Biosciences' Income towards Parent Company (Yearly) stood at -$44.3 million in 2020, then plummeted by 166.37% to -$117.9 million in 2021, then tumbled by 47.47% to -$173.9 million in 2022, then declined by 21.67% to -$211.6 million in 2023, then crashed by 52.18% to -$322.1 million in 2024.